MedTrace Logo

Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

NCT00903721 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3806

Last updated 2022-02-16

No results posted yet for this study

Summary

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

mometasone furoate

Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg) Duration: up to 6 months

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2012-10-31
Completion
2012-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00903721 on ClinicalTrials.gov